Aron-Wisnewsky J Clément K

The gut microbiome, diet, and links to cardiometabolic and chronic disorders.

Nat Rev Nephrol. 12: 169-181Lau WL Savoj J Nakata MB Vaziri ND

Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.

Clin Sci (Lond). 132: 509-522Anders HJ Andersen K Stecher B

The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease.

Kidney Int. 83: 1010-1016Peng J Xiao X Hu M Zhang X

Interaction between gut microbiome and cardiovascular disease.

Life Sci. 214: 153-157

Cancer and the microbiota.

Science. 348: 80-86Isolauri E Kalliomäki M Laitinen K Salminen S

Modulation of the maturing gut barrier and microbiota: a novel target in allergic disease.

Curr Pharm Des. 14: 1368-1375

The dialog between microbiota and the immune system: shaping the partners through development and evolution.

Semin Immunol. 24: 1-2

Huttenhower C , Gevers D, Knight R, et al, The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome.

Nature. 486: 207-214Pflughoeft KJ Versalovic J

Human microbiome in health and disease.

Annu Rev Pathol. 7: 99-122Lau WL Kalantar-Zadeh K Vaziri ND

The gut as a source of inflammation in chronic kidney disease.

Nephron. 130: 92-98Vaziri ND Wong J Pahl M Piceno YM Yuan J Desantis TZ et al.

Chronic kidney disease alters intestinal microbial flora.

Kidney Int. 83: 308-315Gregor MF Hotamisligil GS

Inflammatory mechanisms in obesity.

Annu Rev Immunol. 29: 415-445Ley RE Bäckhed F Turnbaugh P Lozupone CA Knight RD Gordon JI

Obesity alters gut microbial ecology.

Proc Natl Acad Sci U S A. 102: 11070-11075Bäckhed F Manchester JK Semenkovich CF Gordon JI

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Proc Natl Acad Sci U S A. 104: 979-984Ellekilde M Selfjord E Larsen CS Jakesevic M Rune I Tranberg B et al.

Transfer of gut microbiota from lean and obese mice to antibiotic-treated mice.

Sci Rep. 4: 5922Le Chatelier E Nielsen T Qin J Prifti E Hildebrand F Falony G et al.

Richness of human gut microbiome correlates with metabolic markers.

Nature. 500: 541-546Larsen N Vogensen FK van den Berg FW Nielsen DS Andreasen AS Pedersen BK et al.

Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults.

PLoS One. 5: e9085Wu X Ma C Han L Nawaz M Gao F Zhang X et al.

Molecular characterisation of the faecal microbiota in patients with type II diabetes.

Curr Microbiol. 61: 69-78Qin J Li Y Cai Z Li S Zhu J Zhang F et al.

A metagenome-wide association study of gut microbiota in type 2 diabetes.

Nature. 490: 55-60Sabatino A Regolisti G Cosola C Gesualdo L Fiaccadori E

Intestinal microbiota in type 2 diabetes and chronic kidney disease.

Curr Diab Rep. 17: 16Tao S Li L Liu Y Ren Q Shi M Liu J et al.

Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition.

Acta Diabetol. 56: 581-592Simonsen JR Harjutsalo V Järvinen A Kirveskari J Forsblom C Groop PH et al.

Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study.

BMJ Open Diabetes Res Care. 3e000067Canfora EE Meex RCR Venema K Blaak EE

Gut microbial metabolites in obesity, NAFLD and T2DM.

Nat Rev Endocrinol. 15: 261-273Vatanen T Franzosa EA Schwager R Tripathi S Arthur TD Vehik K et al.

The human gut microbiome in early-onset type 1 diabetes from the TEDDY study.

Nature. 562: 589-594de Goffau MC Luopajärvi K Knip M Ilonen J Ruohtula T Härkönen T et al.

Fecal microbiota composition differs between children with β-cell autoimmunity and those without.

Diabetes. 62: 1238-1244Sanna S van Zuydam NR Mahajan A Kurilshikov A Vich Vila A Võsa U et al.

Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases.

Nat Genet. 51: 600-605Schugar RC Shih DM Warrier M Helsley RN Burrows A Ferguson D et al.

The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue.

Cell Rep. 19: 2451-2461Heianza Y Sun D Li X DiDonato JA Bray GA Sacks FM et al.

Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial.

Gut. 68: 263-270Meijers BK Claes K Bammens B de Loor H Viaene L Verbeke K et al.

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.

Clin J Am Soc Nephrol. 5: 1182-1189Kikuchi K Saigusa D Kanemitsu Y Matsumoto Y Thanai P Suzuki N et al.

Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.

Nat Commun. 10: 1835Koeth RA Lam-Galvez BR Kirsop J Wang Z Levison BS Gu X et al.

l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans.

J Clin Invest. 129: 373-387Smits LP Kootte RS Levin E Prodan A Fuentes S Zoetendal EG et al.

Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome.

J Am Heart Assoc. 7e008342Kalantar-Zadeh K Fouque D

Nutritional management of chronic kidney disease.

N Engl J Med. 377: 1765-1776

A review of potential metabolic etiologies of the observed association between red meat consumption and development of type 2 diabetes mellitus.

Metabolism. 64: 768-779Medawar E Huhn S Villringer A Veronica Witte A

The effects of plant-based diets on the body and the brain: a systematic review.

Transl Psychiatry. 9: 226David LA Maurice CF Carmody RN Gootenberg DB Button JE Wolfe BE et al.

Diet rapidly and reproducibly alters the human gut microbiome.

Nature. 505: 559-563Kalantar-Zadeh K Joshi S Schlueter R Cooke J Brown-Tortorici A Donnelly M et al.

Plant-dominant low-protein diet for conservative management of chronic kidney disease.

Nutrients. : 12:1931Lai S Molfino A Testorio M Perrotta AM Currado A Pintus G et al.

Effect of low-protein diet and inulin on microbiota and clinical parameters in patients with chronic kidney disease.

Nutrients. 11: 3006Derrien M van Passel MW van de Bovenkamp JH Schipper RG de Vos WM Dekker J

Mucin-bacterial interactions in the human oral cavity and digestive tract.

Gut Microbes. 1: 254-268Everard A Belzer C Geurts L Ouwerkerk JP Druart C Bindels LB et al.

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.

Proc Natl Acad Sci U S A. 110: 9066-9071Shin NR Lee JC Lee HY Kim MS Whon TW MS, Lee et al.

An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice.

Gut. 63: 727-735Anhê FF Roy D Pilon G Dudonné S Matamoros S Varin TV et al.

A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice.

Gut. 64: 872-883Lee DM Battson ML Jarrell DK Hou S Ecton KE Weir TL et al.

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.

Cardiovasc Diabetol. 17: 62Mishima E Fukuda S Kanemitsu Y Saigusa D Mukawa C Asaji K et al.

Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model.

Am J Physiol Renal Physiol. 315: F824-F833van Bommel EJM Herrema H Davids M Kramer MHH Nieuwdorp M van Raalte DH

Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: results of a double-blind randomized trial in patients with type 2 diabetes.

Diabetes Metab. 46: 164-168Pandey KR Naik SR Vakil BV

Probiotics, prebiotics and synbiotics- a review.

J Food Sci Technol. 52: 7577-7587Bekkering P Jafri I van Overveld FJ Rijkers GT

The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes.

Expert Rev Clin Immunol. 9: 1031-1041Mishra SP Wang S Nagpal R Miller B Singh R Taraphder S et al.

Probiotics and prebiotics for the amelioration of type 1 diabetes: present and future perspectives.

Microorganisms. 7: 67Hooper LV Midtvedt T Gordon JI

How host-microbial interactions shape the nutrient environment of the mammalian intestine.

Annu Rev Nutr. 22: 283-307

The interplay between fiber and the intestinal microbiome in the inflammatory response.

Adv Nutr. 4: 16-28Vaziri ND Liu SM Lau WL Khazaeli M Nazertehrani S Farzaneh SH et al.

High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease.

PLoS One. 9e114881Kieffer DA Piccolo BD Vaziri ND Liu S Lau WL Khazaeli M et al.

Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats.

Am J Physiol Renal Physiol. 310: F857-F871Tayebi Khosroshahi H Vaziri ND Abedi B Asl BH Ghojazadeh M Jing W et al.

Effect of high amylose resistant starch (HAM-RS2) supplementation on biomarkers of inflammation and oxidative stress in hemodialysis patients: a randomized clinical trial.

Hemodial Int. 22: 492-500Laffin MR Tayebi Khosroshahi H Park H Laffin LJ Madsen K Kafil HS et al.

Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: Microbial analysis from a randomized placebo-controlled trial.

Hemodial Int. 23: 343-347Tiderencel KA Hutcheon DA Ziegler J

Probiotics for the treatment of type 2 diabetes: a review of randomized controlled trials.

Diabetes Metab Res Rev. 36: e3213Dolpady J Sorini C Di Pietro C Cosorich I Ferrarese R Saita D et al.

Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment.

J Diabetes Res. 20167569431Hansen CHF Larsen CS Petersson HO Zachariassen LF Vegge A Lauridsen C et al.

Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice.

Diabetologia. 62: 1689-1700Tunapong W Apaijai N Yasom S Tanajak P Wanchai K Chunchai T et al.

Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats.

Eur J Nutr. 57: 2091-2104Amirpour M Fanaei H Karajibani M Montazerifar F Dashipour A

Beneficial effect of symbiotic supplementation during pregnancy in high fat diet-induced metabolic disorder in rats: role of chemerin.

Obes Med. 19100247Sabico S Al-Mashharawi A Al-Daghri NM Wani K Amer OE Hussain DS et al.

Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial.

Clin Nutr. 38: 1561-1569Ebrahimi ZS Nasli-Esfahani E Nadjarzade A Mozaffari-Khosravi H

Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial.

J Diabetes Metab Disord. 16: 23Khalili L Alipour B Asghari Jafar-Abadi M Faraji I Hassanalilou T Mesgari Abbasi M et al.

The effects of Lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus: a randomized controlled trial.

Iran Biomed J. 23: 68-77Razmpoosh E Javadi A Ejtahed HS Mirmiran P Javadi M Yousefinejad A

The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial.

Diabetes Metab Syndr. 13: 175-182Farrokhian A Raygan F Soltani A Tajabadi-Ebrahimi M Sharifi Esfahani M Karami AA et al.

The effects of synbiotic supplementation on carotid intima-media thickness, biomarkers of inflammation, and oxidative stress in people with overweight, diabetes, and coronary heart disease: a randomized, double-blind, placebo-controlled trial.

Probiotics Antimicrob Proteins. 11: 133-142Firouzi S Majid HA Ismail A Kamaruddin NA Barakatun-Nisak MY

Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial.

Eur J Nutr. 56: 1535-1550Uusitalo U Liu X Yang J Aronsson CA Hummel S Butterworth M et al.

Association of early exposure of probiotics and islet autoimmunity in the TEDDY study.

JAMA Pediatr. 170: 20-28Ho J Nicolucci AC Virtanen H Schick A Meddings J Reimer RA et al.

Effect of prebiotic on microbiota, intestinal permeability, and glycemic control in children with type 1 diabetes.

J Clin Endocrinol Metab. 104: 4427-4440Callaway LK McIntyre HD Barrett HL Foxcroft K Tremellen A Lingwood BE et al.

Probiotics for the prevention of gestational diabetes mellitus in overweight and obese women: findings from the SPRING double-blind randomized controlled trial.

Diabetes Care. 42: 364-371Pellonperä O Mokkala K Houttu N Vahlberg T Koivuniemi E Tertti K et al.

Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: a randomized, placebo-controlled, double-blind clinical trial.

Diabetes Care. 42: 1009-1017Kijmanawat A Panburana P Reutrakul S Tangshewinsirikul C

Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: a double-blind randomized controlled trial.

J Diabetes Investig. 10: 163-170Karamali M Dadkhah F Sadrkhanlou M Jamilian M Ahmadi S Tajabadi-Ebrahimi M et al.

Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial.

Diabetes Metab. 42: 234-241Tabrizi R Ostadmohammadi V Lankarani KB Akbari M Akbari H Vakili S et al.

The effects of probiotic and synbiotic supplementation on inflammatory markers among patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.

Eur J Pharmacol. 852: 254-264

Risk and safety of probiotics.

Clin Infect Dis. 60: S129-S134Zein EF Karaa S Chemaly A Saidi I Daou-Chahine W Rohban R

[Lactobacillus rhamnosus septicemia in a diabetic patient associated with probiotic use: a case report].

Ann Biol Clin (Paris). 66: 195-198

Gut microbial short-chain fatty acids and the risk of diabetes (editorial).

Nat Rev Nephrol. 15: 389-390